Skip to main content
SpringerLink
Log in

Dendritic Cells and Immunotherapy for Cancer

  • Progress in Hematology
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Dendritic cells, nature’s adjuvant, are antigen-presenting cells specialized to initiate and regulate immunity. Their potent antigen-presenting function has encouraged targeting of dendritic cells (DCs) for harnessing the immune system against cancer. DCs are efficient at activating not only CD4+ helper T-cells and CD8+ killer T-cells but also B-cells and innate effectors such as natural killer and natural killer T-cells. Early studies of adoptive transfer of tumor antigen-loaded DCs have shown promise. However, DC vaccination is at an early stage, and several parameters still need to be established. The complexity of the DC system brings about the necessity for its rational manipulation for achieving protective and therapeutic immunity in patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pardoll DM. Cancer vaccines.Nat Med. 1998;4:525–531.

    Article  CAS  PubMed  Google Scholar 

  2. Sogn JA. Tumor immunology: the glass is half full.Immunity. 1998; 9:757–763.

    Article  CAS  PubMed  Google Scholar 

  3. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines.Cell. 2001;106:255–258.

    Article  CAS  PubMed  Google Scholar 

  4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity.Nature. 1998;392:245–252.

    Article  CAS  PubMed  Google Scholar 

  5. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future.Int J Cancer. 2001;94:459–473.

    Article  CAS  PubMed  Google Scholar 

  6. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy.Cell. 2001;106:271–274.

    Article  CAS  PubMed  Google Scholar 

  7. Steinman RM. The dendritic cell system and its role in immuno-genicity.Annu Rev Immunol. 1991;9:271–296.

    Article  CAS  PubMed  Google Scholar 

  8. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulo-cyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α.J Exp Med. 1994;179: 1109–1118.

    Article  CAS  PubMed  Google Scholar 

  9. Caux C, Vanbervliet B, Massacrier C, et al. CD34+ hematopoietic progenitors from human cord blood differentiate along 2 independent dendritic cell pathways in response to GM-CSF+ TNF α.J Exp Med. 1996;184:695–706.

    Article  CAS  PubMed  Google Scholar 

  10. Inaba K, Metlay JP, Crowley MT, Steinman RM. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ.J Exp Med. 1990;172:631–640.

    Article  CAS  PubMed  Google Scholar 

  11. Dhodapkar MV, Steinman RM, Sapp M, et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells.J Clin Invest. 1999;104:173–180.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Dhodapkar MV, Krasovsky J, Steinman R, Bhardwaj N. Mature dendritic cells boost functionally superior T cell in humans without foreign helper epitopes.J Clin Invest.2000;107:R9-R14.

    Article  Google Scholar 

  13. Gilboa E. The makings of a tumor rejection antigen.Immunity. 1999;11:263–270.

    Article  CAS  PubMed  Google Scholar 

  14. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy.Annu Rev Immunol. 2000;18:245–273.

    Article  CAS  PubMed  Google Scholar 

  15. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells.Nat Med. 1996;2:52–58.

    Article  CAS  PubMed  Google Scholar 

  16. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.Nat Med. 1998;4:328–332.

    Article  CAS  PubMed  Google Scholar 

  17. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.J Exp Med. 1999;190:1669–1678.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.Cancer Res. 2001;61: 6451–6458.

    PubMed  CAS  Google Scholar 

  19. Salgaller ML, Tjoa BA, Lodge PA, et al. Dendritic cell-based immunotherapy of prostate cancer.Crit Rev Immunol. 1998;18: 109–119.

    Article  CAS  PubMed  Google Scholar 

  20. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.J Exp Med. 2002;195: 1279–1288.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.Proc Natl Acad Sci USA. 2001;98:8809–8814.

    Article  CAS  PubMed  Google Scholar 

  22. Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo.J Exp Med. 2001;194:769–779.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells.Annu Rev Immunol. 2002;20:621–667.

    Article  CAS  PubMed  Google Scholar 

  24. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity.Annu Rev Immunol. 2001;19:47–64.

    Article  CAS  PubMed  Google Scholar 

  25. Dhodapkar K, Krasovsky J, Williamson B, Dhodapkar M. Anti-tumor monoclonal antibodies enhance cross presentation of cellular antigens and the generation of tumor specific killer T cells by dendritic cells.J Exp Med. 2002;195:125–133.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Amigorena S. Fc gamma receptors and cross-presentation in dendritic cells.J Exp Med. 2002;195:F1-F3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Inaba K,Turley S, Yamaide F, et al. Efficient presentation of phago-cytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells.J Exp Med. 1998;188: 2163–2173.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Mahnke K, Guo M, Lee S, et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments.J Cell Biol. 2000;151:673–684.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells.Curr Opin Immunol. 1997;9:10–16.

    Article  CAS  PubMed  Google Scholar 

  30. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance.Proc Natl Acad Sci U SA. 2002;99:351–358.

    Article  CAS  Google Scholar 

  31. Medzhitov R. Toll-like receptors and innate immunity.Nat Rev Immunol. 2001;1:135–145.

    Article  CAS  PubMed  Google Scholar 

  32. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens.J Exp Med. 2001;194:863–869.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide.J Immunol. 1999; 163:2387–2391.

    PubMed  CAS  Google Scholar 

  34. Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI. NKT cells: conductors of tumor immunity?Curr Opin Immunol. 2002;14:165–171.

    Article  CAS  PubMed  Google Scholar 

  35. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-producing NKT responses induced with alpha-galactosylceramide-loaded dendritic cells.Nat Immunol. 2002;3:867–874.

    Article  CAS  PubMed  Google Scholar 

  36. Fujii S, Shimizu K, Steinman RM, Dhodapkar MV. Detection and activation of human V alpha 24+ natural killer T cells using alpha galactosyl ceramide pulsed dendritic cells.J Immunol Methods. 2003;272:147–159.

    Article  CAS  PubMed  Google Scholar 

  37. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues.Nat Rev Immunol. 2002;2:1–8.

    Article  CAS  Google Scholar 

  38. Dubois B, Bridon JM, Fayette J, et al. Dendritic cells directly modulate B cell growth and differentiation.J Leukoc Biol. 1999;66:224–230.

    Article  CAS  PubMed  Google Scholar 

  39. Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL.Nat Immunol. 2002;3:822–829.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity.Cell. 2001;106:259–262.

    Article  CAS  PubMed  Google Scholar 

  41. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, et al. A comparison of 2 types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.Int J Cancer. 2001;93:243–251.

    Article  CAS  PubMed  Google Scholar 

  42. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans.Blood. 2002;100:174–177.

    Article  CAS  PubMed  Google Scholar 

  43. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen specific inhibition of effector T cell function in humans after injection of immature dendritic cells.J Exp Med. 2001;193:233–238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Morse MA, Lyerly HK, Gilboa E, Thomas E, Nair SK. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells.Cancer Res. 1998;58:2965–2968.

    PubMed  CAS  Google Scholar 

  45. Hermans IF, Ritchie DS, Yang J, Roberts JM, Ronchese F. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity.J Immunol. 2000;164:3095–3101.

    Article  CAS  PubMed  Google Scholar 

  46. Medema JP, Schuurhuis DH, Rea D, et al. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells.J Exp Med. 2001;194:657–667.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies.Cancer Res. 1999;59:56–58.

    PubMed  CAS  Google Scholar 

  48. Serody JS, Collins EJ, Tisch RM, Kuhns JJ, Frelinger JA.T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery.J Immunol. 2000;164: 4961–4967.

    Article  CAS  PubMed  Google Scholar 

  49. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients.J Immunol. 2001;166:4254–4259.

    Article  CAS  PubMed  Google Scholar 

  50. Amigorena S. Cancer immunotherapy using dendritic cell-derived exosomes.Medicina (B Aires). 2000;60:51–54.

    PubMed  CAS  Google Scholar 

  51. Nair SK, Heiser A, Boczkowski D, et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.Nat Med. 2000;6:1011–1017.

    Article  CAS  PubMed  Google Scholar 

  52. Gong J, Koido S, Chen D, et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12.Blood. 2002;99:2512–2517.

    Article  CAS  PubMed  Google Scholar 

  53. Heiser A, Coleman D, DannullJ, et al.Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.J Clin Invest. 2002; 109:409–417.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Gilboa E. The risk of autoimmunity associated with tumor immunotherapy.Nat Immunol. 2001;2:789–792.

    Article  CAS  PubMed  Google Scholar 

  55. Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong tumor specific cytolytic responses to autologous tumor loaded dendritic cells.Proc Natl Acad Sci. 2002;99:13009–13013.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, 1230 York Ave, 10021, New York, New York, USA

    David H. Chang & Madhav V. Dhodapkar

  2. Hematology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

    Madhav V. Dhodapkar

Authors
  1. David H. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Madhav V. Dhodapkar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Madhav V. Dhodapkar.

About this article

Cite this article

Chang, D.H., Dhodapkar, M.V. Dendritic Cells and Immunotherapy for Cancer. Int J Hematol 77, 439–443 (2003). https://doi.org/10.1007/BF02986611

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02986611

Keywords

Search

Navigation